Series B funds will enable clinical development of ATV-1601, an oral allosteric AKT1-selective inhibitor for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT), and the advancement of its ...

Atavistik Bio is using the cash to develop “allosteric” medicines it believes can offer precise impact on diseases like myelofibrosis and the blood condition HHT.

Australian environmental technology specialist EWS has established a permanent presence in Canada following a year of ...